本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

GT Biopharma Inc.

0.6774
-0.2432-26.42%
成交量:115.72万
成交额:82.03万
市值:720.49万
市盈率:-0.17
高:0.7713
开:0.7500
低:0.6600
收:0.9206
52周最高:4.10
52周最低:0.5400
股本:1,063.61万
流通股本:926.25万
量比:2.07
换手率:12.49%
股息:- -
股息率:- -
每股收益(TTM):-3.9434
每股收益(LYR):-6.9370
净资产收益率:-181.99%
总资产收益率:-82.45%
市净率:2.52
市盈率(LYR):-0.10

数据加载中...

2025/03/12

SEC问询函

Form CORRESP - Correspondence
2025/02/26

重要事件披露

Form 8-K - Current report
2025/02/21

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/07

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/01/27

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2025/01/27

重要事件披露

Form 8-K - Current report
2024/12/23

招股说明书

Form S-1 - General form for registration of securities under the Securities Act of 1933
2024/11/28

重要事件披露

Form 8-K - Current report
2024/11/21

重要事件披露

Form 8-K - Current report
2024/11/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

重要事件披露

Form 8-K - Current report
2024/08/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/27

SEC问询函

Form CORRESP - Correspondence
2024/06/27

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2024/06/27

重要事件披露

Form 8-K - Current report
2024/06/26

重要事件披露

Form 8-K - Current report
2024/06/20

招股说明书

Form S-1 - General form for registration of securities under the Securities Act of 1933
2024/06/07

重要事件披露

Form 8-K - Current report
2024/05/23

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/05/23

重要事件披露

Form 8-K - Current report